The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.
July 1st 2021
Dr. Sherman discusses the incidence of RET fusions in medullary thyroid cancer and the current clinical landscape of RET inhibitors in the field.
June 29th 2021
The immunotherapy Leukocyte interleukin followed by surgery and radiotherapy, without chemotherapy, significantly improved overall survival compared with standard of care alone in the treatment of patients with advanced primary squamous cell carcinoma of the head and neck.
June 29th 2021
Barbara Burtness, MD, discusses the efficacy of immune checkpoint inhibitors in the treatment of patients with head and neck cancer.
June 6th 2021
Selpercatinib demonstrated evidence of preliminary efficacy and safety in pediatric patients with advanced RET-altered solid tumors.
June 3rd 2021
The addition of the immunotherapy agent toripalimab to gemcitabine plus cisplatin demonstrated superior progression-free survival compared with chemotherapy alone in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma, according to data from the phase 3 JUPITER-02 trial.
June 2nd 2021
Innovative strategies are vital for patients diagnosed with rare cancers, who are frequently at a disadvantage compared with those who have more common malignancies, experts say.
May 26th 2021
Taofeek Owonikoko MD, PhD, MSCR, discusses the efficacy of selpercatinib in pre-treated and treatment-naive patients with RET fusion–positive medullary thyroid cancer.
May 25th 2021
Julie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.
May 24th 2021
A biologics license application has been submitted to the FDA for the PD-1 monoclonal antibody penpulimab for the third-line treatment of patients with metastatic nasopharyngeal carcinoma.
May 21st 2021
Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.
May 21st 2021
The combination of the anti–PD-1 tislelizumab and chemotherapy was found to significantly improve progression-free survival compared with chemotherapy alone in the frontline treatment of patients with recurrent or metastatic nasopharyngeal cancer, meeting the primary end point of the phase 3 RATIONALE 309 trial.
May 18th 2021
Cell-free methylated DNA immunoprecipitation-sequencing uses plasma cell-free methylomes to detect and classify several types of cancer early on, and provides the opportunity to monitor tumors for response to treatment in noninvasive way.
May 13th 2021
Thomas Urban Marron, MD, PhD, describes the patient population included in a phase 1 study examining the use of PGV-001, a neoantigen cancer vaccine, across different malignancies.
April 29th 2021
Ezra Cohen, MD, FRCPSC, FASCO, discusses future research directions for the treatment of patients with head and neck cancer.
April 21st 2021
Although the malignancy has an encouraging survival rate, it is necessary to be aware of the complexity of nasopharyngeal cancer.
April 19th 2021
Dr. Saba shares the ins and outs of nasopharyngeal carcinoma, ongoing clinical trials, and the complexities of managing the rare disease.
April 15th 2021
Nabil F. Saba, MD, FACP, discusses some of the unique characteristics of nasopharyngeal carcinoma.
April 14th 2021
Innovative robotic technology helps to improve surgical outcomes and safety for patients while advancing the field of ENT surgery.
April 10th 2021
Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.
April 8th 2021
The FDA has granted a fast track designation to the soluble LAG-3 protein eftilagimod alpha for use in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.